-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease
.
Because patients often have other atopic diseases such as allergic rhinitis and asthma, it is considered a systemic disease
Quality of life children
Eli Lilly said on Tuesday that the third phase III study of lebrikizumab in patients with moderate to severe atopic dermatitis (AD) met all its primary and key secondary endpoints
.
In this latest study, called ADhere, 228 adults and adolescents with moderate to severe AD were randomized to receive topical corticosteroids in combination with lebrikizumab or placebo
.
The primary endpoint of the trial: At week 16, the Investigator’s Overall Assessment (IGA) score for clear or almost clear skin was reduced by at least 2 points compared with the baseline; the Eczema Area and Severity Index (EASI) score was compared with the baseline Change ≥75%
Eli Lilly noted that the most common adverse events reported in the trial included conjunctivitis and headaches in patients treated with lebrikizumab
.
The complete research results will be announced at a scientific conference in 2022
Eli Lilly noted that the most common adverse events reported in the trial included conjunctivitis and headaches in patients treated with lebrikizumab
Original source:
Original source:https://firstwordpharma.
https://firstwordpharma.
com/story/5466335 https://firstwordpharma.
com/story/5466335 Leave a message here
